Telitacicept for primary membranous nephropathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a new drug called telitacicept in people with primary membranous nephropathy, a kidney condition that causes protein leakage in urine. It aims to see if the drug can reduce protein loss and protect kidney function, potentially slowing the disease's progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with primary membranous nephropathy via kidney biopsy.
- You have nephrotic syndrome, meaning you lose at least 3.5 grams of protein in your urine daily and have low blood albumin (below 3.0 g/dL).
- You are considered at high risk for the disease getting worse, based on specific kidney function and protein loss levels.
- You have not used steroids, immunosuppressants, or certain other treatments in the last 3 months.
- You agree to use effective contraception during the study (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called JMT601 for people with primary membranous nephropathy (a kidney condition causing protein leakage). The goal is to see if the medicine can reduce protein in the urine while being safe.
This trial tests a new drug called YK012 for people with primary membranous nephropathy, a kidney disease where protein leaks into the urine. The goal is to see if this treatment can reduce protein loss and protect kidney function.
This study tests an investigational drug called povetacicept for people with primary membranous nephropathy, a kidney disease. Researchers want to see if it is safe and helps reduce protein in the urine.
This trial studies how well rituximab works in primary membranous nephropathy (a kidney condition) either by itself or with corticosteroids (steroids). It aims to see which approach controls protein leakage in the urine and protects kidney function.
This Phase 1 study tests a skin-under-the-bone (subcutaneous) antibody medicine that targets CD20 on certain immune cells. It aims to see safety and how the drug may work in people with primary membranous nephropathy, a kidney disease that can cause high urine protein.
This trial tests if finerenone, a medicine that may protect the kidneys, can help people with primary membranous nephropathy (a kidney disease that causes protein in urine). It is for adults who are already taking a standard blood pressure medicine but still have protein in their urine.
Hear when a new Primary Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.